Literature DB >> 28774597

Nintedanib reduces radiation-induced microscopic lung fibrosis but this cannot be monitored by CT imaging: A preclinical study with a high precision image-guided irradiator.

Dirk De Ruysscher1, Patrick Vincent Granton2, Natasja Gaby Lieuwes2, Stefan van Hoof2, Lutz Wollin3, Birgit Weynand4, Anne-Marie Dingemans5, Frank Verhaegen2, Ludwig Dubois6.   

Abstract

BACKGROUND: Nintedanib has anti-fibrotic and anti-inflammatory activity and is approved for the treatment of idiopathic pulmonary fibrosis. The aim of this study was to noninvasively assess the efficacy of nintedanib in a mouse model of partial lung irradiation to prevent radiation-induced lung damage (RILD).
METHODS: 266 C57BL/6 adult male mice were irradiated with a single radiation dose (0, 4, 8, 12, 16 or 20Gy) using parallel-opposed fields targeting the upper right lung using a precision image-guided small animal irradiator sparing heart and spine based on micro-CT images. One week post irradiation, mice were randomized across nintedanib daily oral gavage treatment (0, 30 or 60mg/kg). CT density analysis of the lungs was performed on monthly acquired micro-CT images. After 39weeks, lungs were processed to evaluate the fibrotic phenotype.
RESULTS: Although the CT density increase correlated with the radiation dose, nintedanib did not influence this relationship. Immunohistochemical analysis confirmed the ability of nintedanib to reduce the microscopic fibrotic phenotype, in particular interstitial edema, interstitial and perivascular fibrosis and inflammation, and vasculitis.
CONCLUSIONS: Nintedanib reduces radiation-induced lung fibrosis after partial lung irradiation without adverse effects, however, noninvasive CT imaging measuring electron density cannot be applied for monitoring its effects.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Nintedanib; Radiation fibrosis; Radiation pneumonitis; Radiation-induced lung damage; Small animal image-guided precision irradiation

Mesh:

Substances:

Year:  2017        PMID: 28774597     DOI: 10.1016/j.radonc.2017.07.014

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  11 in total

1.  A novel data management platform to improve image-guided precision preclinical biological research.

Authors:  Lucas Persoon; Stefan van Hoof; Frank van der Kruijssen; Patrick Granton; Andrea Sanchez Rivero; Harold Beunk; Ludwig Dubois; Jan-Willem Doosje; Frank Verhaegen
Journal:  Br J Radiol       Date:  2018-10-11       Impact factor: 3.039

Review 2.  Commonalities Between COVID-19 and Radiation Injury.

Authors:  Carmen I Rios; David R Cassatt; Brynn A Hollingsworth; Merriline M Satyamitra; Yeabsera S Tadesse; Lanyn P Taliaferro; Thomas A Winters; Andrea L DiCarlo
Journal:  Radiat Res       Date:  2021-01-01       Impact factor: 2.841

Review 3.  Preclinical models of radiation-induced lung damage: challenges and opportunities for small animal radiotherapy.

Authors:  Mihaela Ghita; Victoria Dunne; Gerard G Hanna; Kevin M Prise; Jaqueline P Williams; Karl T Butterworth
Journal:  Br J Radiol       Date:  2019-02-13       Impact factor: 3.039

Review 4.  Radiation-Induced Lung Injury: Assessment and Management.

Authors:  Alexander N Hanania; Walker Mainwaring; Yohannes T Ghebre; Nicola A Hanania; Michelle Ludwig
Journal:  Chest       Date:  2019-04-15       Impact factor: 9.410

Review 5.  Integrating Small Animal Irradiators withFunctional Imaging for Advanced Preclinical Radiotherapy Research.

Authors:  Mihaela Ghita; Kathryn H Brown; Olivia J Kelada; Edward E Graves; Karl T Butterworth
Journal:  Cancers (Basel)       Date:  2019-02-01       Impact factor: 6.639

Review 6.  Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.

Authors:  Lutz Wollin; Jörg H W Distler; Elizabeth F Redente; David W H Riches; Susanne Stowasser; Rozsa Schlenker-Herceg; Toby M Maher; Martin Kolb
Journal:  Eur Respir J       Date:  2019-09-19       Impact factor: 16.671

7.  Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity.

Authors:  Linda Spiegelberg; Stefan J van Hoof; Rianne Biemans; Natasja G Lieuwes; Damiënne Marcus; Raymon Niemans; Jan Theys; Ala Yaromina; Philippe Lambin; Frank Verhaegen; Ludwig J Dubois
Journal:  Radiother Oncol       Date:  2019-08-17       Impact factor: 6.280

8.  A scoping review of small animal image-guided radiotherapy research: Advances, impact and future opportunities in translational radiobiology.

Authors:  Kathryn H Brown; Mihaela Ghita; Ludwig J Dubois; Dirk de Ruysscher; Kevin M Prise; Frank Verhaegen; Karl T Butterworth
Journal:  Clin Transl Radiat Oncol       Date:  2022-04-06

Review 9.  Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.

Authors:  Pilar Rivera-Ortega; Conal Hayton; John Blaikley; Colm Leonard; Nazia Chaudhuri
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

10.  Inter-observer variability of organ contouring for preclinical studies with cone beam Computed Tomography imaging.

Authors:  Georgios Lappas; Nick Staut; Natasja G Lieuwes; Rianne Biemans; Cecile J A Wolfs; Stefan J van Hoof; Ludwig J Dubois; Frank Verhaegen
Journal:  Phys Imaging Radiat Oncol       Date:  2022-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.